作者
Sumanta Kumar Pal, Karen Reckamp, Hua Yu, Robert A Figlin
发表日期
2010/11/1
来源
Expert opinion on investigational drugs
卷号
19
期号
11
页码范围
1355-1366
出版商
Taylor & Francis
简介
Importance of the field: The evolution of targeted therapies is dependent upon identification of cellular moieties that can be pharmacologically modulated. As one such example, the serine-threonine kinase Akt was identified nearly two decades ago. Since then, its role in mediating multiple signaling cascades (ultimately leading to cell growth and proliferation) has since been identified. More recently, several agents have been developed that antagonize Akt – these agents are in various stages of clinical testing.
Areas covered in this review: Herein, we outline development of several promising Akt inhibitors, including perifosine, MK-2206, RX-0201, PBI-05204, GSK2141795 and others.
What the reader will gain: The reader will gain insight into the current pipeline of Akt inhibitors, and the degree to which these agents have been examined both clinically and preclinically.
Take home message: With an emerging …
引用总数
2010201120122013201420152016201720182019202020212022202320244183742292531212077111234
学术搜索中的文章
SK Pal, K Reckamp, H Yu, RA Figlin - Expert opinion on investigational drugs, 2010